TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 ETAS ID: TM595491

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Second Amended and Restated Intellectual Property Security Agreement

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Akebia Therapeutics, Inc.		06/01/2020	Corporation: DELAWARE
Keryx Biopharmaceuticals, Inc.		06/01/2020	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Biopharma Credit PLC
Street Address:	51 New North Road
Internal Address:	c/o Beaufort House
City:	Exeter EX4 4EP
State/Country:	D.C.
Postal Code:	20006
Entity Type:	Public Limited Company: UNITED KINGDOM

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	4956680	AURYXIA

CORRESPONDENCE DATA

Fax Number: 2028874288

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2028874000

Email: dlee@akingump.com

Correspondent Name: David C. Lee

Address Line 1: 2001 K Street N.W. Address Line 4: Washington, D.C. 20006

DOMESTIC REPRESENTATIVE

David C. Lee Name:

Address Line 1: 2001 K Street N.W.

Address Line 4: Washington, D.C. 20006

NAME OF SUBMITTER:	David C. Lee
SIGNATURE:	/David C. Lee/
DATE SIGNED:	09/02/2020

Total Attachments: 9 source=Pharmakon - Akebia -- Second Am. IP#page1.tif source=Pharmakon - Akebia -- Second Am. IP#page2.tif source=Pharmakon - Akebia -- Second Am. IP#page3.tif source=Pharmakon - Akebia -- Second Am. IP#page4.tif source=Pharmakon - Akebia -- Second Am. IP#page5.tif source=Pharmakon - Akebia -- Second Am. IP#page6.tif source=Pharmakon - Akebia -- Second Am. IP#page7.tif source=Pharmakon - Akebia -- Second Am. IP#page8.tif source=Pharmakon - Akebia -- Second Am. IP#page9.tif

This SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 1, 2020, is made by AKEBIA THERAPEUTICS, INC. and KERYX BIOPHARMACEUTICALS, INC., (the "Grantors" and each a "Grantor"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns in such capacity, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESETH:

WHEREAS, pursuant to the Loan Agreement, dated as of November 11, 2019 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among AKEBIA THERAPEUTICS, INC. ("Borrower"), KERYX BIOPHARMACEUTICALS, INC. (as an additional Credit Party), BIOPHARMA CREDIT PLC (as the "Collateral Agent"). BPCR LIMITED PARTNERSHIP (as a "Lender" and successor-in-interest to BioPharma Credit PLC in such capacity) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a "Lender"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of November 25, 2019 in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, each Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor executed and delivered to the Collateral Agent an Intellectual Property Security Agreement, dated as of November 25, 2019 and amended and restated as of April 1, 2020 (the "Existing Intellectual Property Security Agreement");

WHEREAS, events impacting certain of the Intellectual Property Collateral (defined below) have subsequently occurred and, pursuant to the Guaranty and Security Agreement, the Grantors are required to execute and deliver to the Collateral Agent this Second Amended and Restated Intellectual Property Security Agreement; and

WHEREAS, this Second Amended and Restated Intellectual Property Security Agreement amends and restates the Existing Intellectual Property Security Agreement in its entirety;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. <u>Defined Terms</u>. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. <u>Grant of Security Interest in IP Collateral</u>. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Intellectual Property Collateral"):

- (a) any and all United States Patents, Trademarks and other Intellectual Property and IP Licenses (including any IP Licenses under the Current Company IP Agreements to which a Grantor is a party and the rights of such Grantor thereunder, and all of a Grantor's right, title and interest in, to and under any Internet Domain Names and Software) owned by a Grantor, in each case, relating to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in the Territory, including, without limitation, those referred to on Schedule 1 hereto; and
- (b) all proceeds, products, accessions, rents and profits of or in respect of any of the foregoing.
- Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Second Amended and Restated Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the obligations, rights and remedies of such Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
- Section 4. <u>Grantor Remains Liable</u>. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Intellectual Property and IP Licenses subject to a security interest hereunder.
- Section 5. <u>Counterparts.</u> This Second Amended and Restated Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.
- Section 6. Governing Law. This Second Amended and Restated Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without regard to any principle of conflicts of law that could require the application of the law of any other jurisdiction.

IN WITNESS WHEREOF, each Grantor has caused this Second Amended and Restated Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

AKEBIA THERAPEUTICS, INC.

as Grantor

By:

Name: John P\Butler

Title: President and Chief Executive Officer

KERYX BIOPHARMACEUTICALS, INC.

as Grantor

Ву:

Name: John P.Quele

Title: Disector

Signature Page to Second Amended and Restated Intellectual Property Security Agreement

ACCEPTED AND AGREED as of the date first above written.

BIOPHARMA CREDIT PLC, as Collateral Agent

By: Pharmakon Advisors, LP, its investment Manager

By: Pharmakon Management L.L.C.

its General-Ranner

Names Pedro Gonzalez de Cosio

Tide/ Managing Member

Signature Page to Second Amended and Restated Intellectual Property Security Agreement

SCHEDULE I
TO
SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

Intellectual Property

1. REGISTERED PATENTS, PATENT APPLICATIONS AND PATENT LICENSES

1 a a a a a a a a a a a a a a a a a a a
Panion & Bi In Force Biotech Inc.
ć
randing Rinterth for
Panion & BF
In Force Biotech Inc
Panion & BF
In Force Biotech Inc
Panion & BF
In Force Biotech Inc
In Force Biotech Inc.
Panion & BF
Biotech Inc

THEREOF AND METHODS OF MAKING SAME	FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL. GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL. GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL- GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL- GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL- GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME
	Panion & BF Biotech Inc.	Panion & BF Biotech Inc.	Panion & BF Biotech Inc.	Panion & BF Biotech Inc.	Panion & BF Biotech Inc.	Pamion & BF Biotech Inc.	Panion & BF Biotech Inc.
	In Force	In Force	In Force	In Force	In Force	In Force	In Force
	5/3/2016	3/14/2018	F10/2012	10/30/2012	6/17/2014	S102/6/9	9/12/2017
	9,328,133	0.913,821	8.093,423	8,299,298	8,754.257	9,050,316	9,757,416
	2/18/2004	2/18/2004	8/18/2006	8/18/2006			8/18/2006
	14/502,774	15/143.987	12/064,058	13/289.048	13/661.558	14/306.756	14/701,933
	P20001US7	P20001US8	P20002US1	P200021(S2	P20002US3	P20062US4	P20002U.S\$

					<u></u>			
PHARMACEUTICAL- GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME	PHARMACEUTICAL- GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MARTING SAME	METHOD FOR TREATING RENAL FAILURE PHARMACEUTICAL-	GRADE FERRIC CITRATE METHOD OF REVERSING, PREVENTING OR STABILIZING SOFT TISSUE CALCIFICATION	METHOD OF TREATING CHRONIC KIDNEY DISEASE	FERRIC CITRATE DOSAGE FORMS	FERRIC CITRATE DOSAGE FORMS	FERRIC CITRATE DOSAGE FORMS	USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
Panion & BF Biotech Inc.	Panion & BF Biotech Inc	HSU, Chen Hsing Panion & BF	Biotech Inc. Panion & BF Biotech Inc.	Panion & BF Biotech Inc.	Keryx Biopharmaceuticals, Inc.	Keryx Biopharmaceuticals, Inc.	Keryx Bropharmaceuticals. Inc.	Keryx Biopharmaceuticals, Inc.
(Abandone d in favor of filing P20002US 8	Pending	In Force	In Force In Force	Pending	In Force	In Force	Pending	Pending
		2/19/1998	6/7/2005		7/12/2016	5/28/2019		
		8,753,706	6.903,235		9,387,191	10,300,039		
9007.8178	3/27/2/020	2/3/1907	10/8/2003	1/26/2007	7/21/2010	5/19/2016	4/5/2019	10/8/2018
16/352/455	16/832,101	08/794.328	10/682.045	15/814.767	13/255/326	15/159,008	16376,907	16/154.268
P20002US7	P20002US8	P20003US1	P20004US P20005US1	P20006US2	P20007U.S1	P20007US3	P20007US4	

USE OF FERRIC CITRATE	IN THE TREATMENT OF	AND THE REDUCTION OF	MORTALITY AND	MORBIDITY RELATED TO	ADVERSE CARDIAC	EVENTS IN CHRONIC	KIDNEY DISEASE	PATIENTS	USE OF FERRIC CITRATE	IN THE TREATMENT OF	IRON-DEFICIENCY	ANEMIA	HIGH PURITY FERRIC	CITRATE, METHODS OF	MANUFACTURE AND USES	FOR THE SAME	IRON (III) CITRATE,	SUBSTANTIALLY FREE OF	BETA-IRON HYDROXIDE	OXIDE	IRON (III) CITRATE.	SUBSTANTIALLY FREE OF	BETA-IRON HYDROXIDE	OXIDE	TABLET CONTAINING	FERRIC CITRATE
				50		Keny	rmacenticals,			Kenx	irmaceuticals.			Keryx	irmaceuticals.					Japan Tobacco, Inc.				Japan Tobacco, Inc.		Japan Tobacco, Inc.
	100		36 3 3 3 3 3 3 3 3 3					Pending				Pending				Pending				017 Issued				Pending		Pending
			eri Pri Annana Pri Pri	00 00 00 00 00 00 00 00 00 00 00 00 00						31 31 31	97 20 2									9,624,155 4/18/2017						
				•				12/11/2018				3/3/2016				12/18/2019				2/19/2014 9				3/3/2017		6/12/2019
			: ::					16/216,772				15/553,348				16/719.570				14/184,062				15/449,132		16/438,694
			: ::		35 - 35 - 35 - 35 - 35 - 35 - 35 - 35 -			P20009US2				P20010US1				P20011US7										200 200 200 200 200 200 200 200 200 200

TRADEMARK REGISTRATIONS!

													ŝ					
													į					
													ì					
													į					
													Ì					
													Š					
			Ś		١													
			ì	ĺ	Ì	i							į					
			Ċ	ŀ	į	١							ì					
			Ì			ì							Š					
			ï		١	١							Ì	ŀ				
					٩	į							į	ŀ				
			٠	٠										ŀ				
٠	•					٠	٠		ċ			٠		ì				
									ì	ુ	ì	i	į	١				
									3	Ċ	ŝ	ì	ì	į.				
									ì	ò	ì	è	ì	ŀ				
								į	ŕ	۰	۱	Š	į	Š.				
								٩	۰	۰	٩	t		ì				
										ċ	٠	١	ì	ł				
										ř	÷		ì	l				
										ï	ĭ			ì				
									9	1	į	١	3	į				
										Ŷ.	١	۱	ì	l				
									ò	S	ļ	ì	í	Ì				
									٩	ù		۶		i				
										٥	0	í	١	١				
										3	Ó	۱	ď	ì				
									ì	٩	ż	١		ì				
								ì	ř)	ļ	è		١				
						Š								١				
				۱		٠	۱		•	i	1	•		١				
								1		ŕ	ŀ			١				
										1	•	9		١				
										Ľ	*	:		i				
										¢	2	١		į				
								١		٠	٠	١		i				
									•	۶	ř	Ś		;				
										ŕ		i		į				
									٠	٠	۶			i				
								í	è	ç	٥	Ś		ŀ				
										Ç	٦	ţ	į	ţ				
										¢		ì		l				
									Ć	١	ė	١		١				
								i	i	Ī	Ī	ì		ŝ				
۲	٠		٠		•	۰	۲		•		•	•		ì				
														ì				
									١		٠							
										`;	ř	į						
										ż	٩	:		į				
									١	v	٠	٠		١				
									۶	3	٠	٠		ì				
														ì				
										4	ý	١						
										1	١	;		١				
										1				1				
														Section 25				
										() · · ·				Action to the second				
										() ·				The second second				
										(40) ·				The state of the s				
										(401 - ·				Contract of the Contract of th				
					4					C+				Contraction of the Contract of				
										Can	֡			Contraction of the Contraction o				
										C+01-								
										Contract of the Contract of th				Contract of the second second second				
										Carry or the Contract				Commence of the contract of th				
										C+01				Commence of the contract of th				
										Carried to the contraction of th				Control of the Contro				
										Carry to the second of the second				The state of the s				
										Court contract contract				The Part of the Contract of th				
										Carry of the second of the second				The state of the s				
										Charles of the Contract of the				The state of the s				
										Charles to the transfer of the American				Control of the Contro				
										Charles and the contract of th				Control of the Contro				
										Carried to the section of the Carried Control				Control of the Contro				
										Carry of the second of the sec				Control of the Contro				
										Catholic Property and American				Control of the Contro				
										Contract the second sec				The state of the s				
										the state of the s								
		The second secon								the state of the s				Control of the Contro				
										Carlot of the Control				Control of the Contro				
										Charter of the Contract of the				Control of the Contro				
										Carlo to the transfer of the Allendary of the transfer of the				Control of the Contro				
										C+04-04-05-05-05-05-05-05-05-05-05-05-05-05-05-				The state of the s				
										Carlo				The state of the s				
										Charles and American to the Contraction of the Cont				The state of the s				
										Carlo I to the contract of the				Control of the Contro				
										Carlot of the second of the se								
										Charles to the contract of the								
										Carlo III to the contract of t				The state of the s				
										Carl and the contract of the c				The second secon				
										Cack to the contract of the co				The state of the s				
										Cack to the contract of the co				The state of the s				
										Carlot of the contract of the Carlot of the	2000 - # 00 00 00 00 00 00 00 00 00 00 00 00 0							
										(45) - ** ** (44) (4) ** (4) *								
										(401 - 1 May 200) May V Contact (5								
										Carlo in the contract of the c								
										Card of the second of the seco								
										Carlot of the Ca								
										Charles of the contract of the								
										Charles of the Contract of the								
										Charles of the American American Contraction of the								
										Charles of the Committee of the Committe								
										C+04								
										Charles and the second of the								
										Contract to the contract to th								
							-			Charles and Charle								
							-			Circles American Contraction of the Contraction of								
							-			Charles of the Contract of the								
							-											
							-											
							-											
							-			Carry Contract Contra								
							-											
							-											
							-											

¹NTD: Any trademarks which are not part of the Collateral have been removed, but these are still referenced in the perfection certificate.

	٠					1			٠.			٥	er.		5
Ì			1		Ī	ï		Ī	Ī	١	ï	ï	•		1
Ì								į	1	ŕ					1
									5	Ų					į.
į	Ì							•	ì	Š					
									•	3					1
	ŀ								Š	3					Ì.
	Š								Š	,					1
ì	ì								ì	š					1
į	١								ì	~					1
	į				,	ċ				Š	ì				į.
	١			Š				•	÷						١.
	١			ì		í			Š	Ö	7			:	1
	ļ		ŀ	`	ì			,		~	í		2		ì
	ì		•		•				~	~			~	័	Ü
	١			~	ľ	•	ĩ	ř	`	~	•	•	~~	~	ì
	Ì														ŧ
	į														ł.
	١												V	3	ŀ
	١												***	٠	1
	١												~	Ś	ŧ.
	١												50	,	3
	:												C	9	Ţ.
													~	•	į
	:														×
													~	Š	1
	*												×	-	j
			٠	4	÷	٠			٠		١	٥			4
	****														1
															1
															i
													٠	5	
													٥	ÿ	
	1												3	ξ,	
	1												ű	ò	
													0		
													ì	•	
	1			1	•	:		1		Ī		_			1
													્ર	:	ä
													C	٥	1.
													Ç	V	1
													C	Ś	1
	į												**	ند	Ş
													્ડ્ર	÷	ų
													r)	ž,	ì
											_		_	_	1
		ŀ													1
		к													· 5 ·
															1
													Ŋ	9	1
													773	333	
													772	000	***************************************
													772 00	300	***************************************
													772 000	22.200	
													272 000 20	30, 32, 300	
													772 00070	00000000	
													772 00070 1	0000000000	
													77 2000 70 1 5	000.7%.7.00	
													272 000 70 C	300000000000000000000000000000000000000	
						一个有一个人的 医二种 医氯化二烷酯							272 000/20 Care		
					The second of th	一个一位 古 经一个人 医乳头 "你就是你一个家伙,我们们							272 000/20 Parent		
						一个一位 古 经一个人 古经人 古 医乳花 一定的 医二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十							272 000/20 Commercial		
						一个一位 古 经一个人 古诗人 古 医乳花 一定是有一定的人 人名马达			***				272 000 70 Paris a		
					The second of th				***				272 000/20 Caronia a		
													775 000 70 P. W. W. W. W. W.		
						一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个							272 WUC/ 20 C. WOJE C. C.	Ca New Stolett - od 1987, 1999	
					1	一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个							772 000 70 Francisco a	Sing Published of Carlotte	
						一个一位 不 经一个人 医硫酸二甲基氯化二甲基化甲基化物 人名 医医囊结节的 人名英格兰							772 000 70 Command of the command		
						一个一位 不 经一个人 医红色 医多种 医二角性 医乳化 人名英捷勒特 人名英格兰人姓氏克尔							772 000/20 F. W. W. W. O. W. W. W. W.		minimum and the second
													772 WWW 70 Franciscon a		
						一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个							272 WOW 20 Francisco a - Transfer 27	OF ATTREBUTE NOVEMBEE OF COMMON	The second secon
						一个一位,这一个人的话, 医多量性 化多异物 医乳头 人名英格兰人名 人名人姓氏克里的变体							272 W.C. 20 P		
						一个一句 不可 化二十二烷 化二氯化二甲烷 医二十二十二烷 医二二烷 医二二烷							272 000/20 Campagna D		
						一个一位 电位 化二十二烷 化二烷 医二烷 经银行 化二烷 医克勒氏病 人名英格兰人姓氏克勒的变体 人名英格兰							272 (AUC) 20 Francisco O		
						一个一位 电电子 计记录机 化电影性 化异苯基酚 化二十二烷基酚 化二二烷二烷 医二烷二烷 医二烷							275 000 20 Francisco B 37 5	States of America President of 1987, 199	
						人名英格兰 经分类的 医多氯化 医结节 经补偿 医腹腔的 人名英格兰人姓氏格兰的变体 医皮肤炎							275 000 20 Francisco Q 37 37 37 F		
						人名英格兰 化二氯化 医腹骨 医阴茎 医阴炎 医二甲基甲基酚 医二甲基甲基酚 医二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二甲基二							272 (2007) 20 Campage Of Campag		
						一个一位 不可能 化二甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基							275 000 70 Francisco Q		
						人名 经存储 化二氯化丁酯 计连接线 化异氯化铁 化二氯甲基苯酚 计一个 化二烷 化硫矿矿 化二烷二烷							272 3000 70 Comment of the second of the s		t to the second
						一个有话的 医外间的 医结膜的 医结节 经补偿 化二氯磺基酚 人名英格兰斯 医人名 化二烷 医眼上颌 医							775 WWW 700 Francisco Q		
					The second of th								275 000/20 Carrows a	Chillien States of Africa Car Newtonical Control of Cartesian	him
					The second of th	人名英格兰 经分类的 医多霉性 医异性 医乳化 化多异氯化物 人名英格兰姓氏 医人名 医二种 医结合性 化二氯酚 医乳脂	1. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						2 1 1 1 2 3 65	A CHIEF STATES OF A HIGH ICE INCREDED ON DAY, JOB	him
					The second of th								272 000020 Comment of the state of the sta		
					The second of th								2 1 1 1 2 3 65	A A A CHIEF STATES OF A HIGHER PROPERTIES - OCCUPANTO	
					The second of th								2 1 1 1 2 3 65		
					The second of th								2 1 1 1 2 3 65	KANALA CHIER SIMICS OF A HELICA - NEEDS CICH - 600 3 XV, 300	
													2 1 1 1 2 3 65	A S A S CONTROL STREET A THE TEST OF THE TOTAL STREET OF THE TOTAL	
					The second of th								2 1 1 1 2 3 65	A 1 X 7 X 1 A 1 CHIER SINGS OF A REFER A 1 NEW SIGNOR 1 90/10/20	

IP LICENSES

- Second Amended and Restated License Agreement between the Borrower and Panion & BF Biotech, Inc., dated April 17, 2019.
- Amended and Restated Sublicense Agreement between Keryx and Japan Tobacco and TORII Pharmaceutical Co., Ltd., dated June 8, ಹವ್
- First Amendment to Amended and Restated Sublicense Agreement between Keryx and Japan Tobacco and TORII Pharmaceutical Co., Ltd., dated June 12, 2013.

TRADEMARK REEL: 007042 FRAME: 0122

RECORDED: 09/02/2020